Breakthrough Alzheimer's Drug Donanemab Offers Hope for Disease Treatment

The drug donanemab has been hailed as a turning point in the fight against Alzheimer's, as it has been shown to slow cognitive decline by about a third. The antibody treatment works by clearing away amyloid, a key feature of Alzheimer's disease. While the drug's effects may be modest and there were significant side effects, the results provide further confirmation that removing amyloid from the brain may change the course of Alzheimer's. Experts believe that we are on the edge of significant change in the landscape of dementia treatment, but the NHS is not yet ready to deliver these emerging Alzheimer's disease drugs at scale.